Jazz Pharmaceuticals (JAZZ) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
- Market cap
- $15.4B
- As of Nov 17, 2026
- P/E
- 74.38x
- Trailing twelve months
- P/B
- 3.67x
- Latest reported equity
- P/S
- 3.26x
- Trailing twelve months
- ROE
- 4.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $15.4B
- As of Nov 17, 2026
- P/E
- 74.38x
- Trailing twelve months
- P/B
- 3.67x
- Latest reported equity
- P/S
- 3.26x
- Trailing twelve months
- ROE
- 4.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
74.38x
P/B
3.67x
P/S
3.26x
Earnings and dividend metrics▾
Earnings
EPS
$3.23
Earnings per share
BPS
$65.50
Book value per share
ROE
4.9%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $3.23 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $65.50 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 4.9%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 10.4% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.13B+10.4%
$1.06B
Jul–Sep '24
$1.13B
Jul–Sep '25
$1.24B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 2, 2026.
- Earnings per share decreased 283.3% from the same quarter a year earlier.
- Revenue increased 10.4% from the same quarter a year earlier.
- Operating income decreased 812.1% from the same quarter a year earlier.
- Net income decreased 292.4% from the same quarter a year earlier.
Filed Nov 2, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- COZADD BRUCE CDirector · Nov 6, 2026Open-market sale68,808 shares · $16.2MAvg. price $235.9539
Show 4 price lots
- 27,714 shares × $234.9122$6.5M
- 24,483 shares × $236.844$5.8M
- 10,688 shares × $235.822$2.5M
- 5,923 shares × $237.3869$1.4M
- COZADD BRUCE CDirector · Nov 6, 2026Option exercise86,500 shares · $11.8MAvg. price $136.18
Show 2 price lots
- 85,766 shares × $136.18$11.7M
- 734 shares × $136.18$100K
- Carr PatriciaSVP, Chief Accounting Officer · Nov 4, 2026Open-market sale1,413 shares · $327KAvg. price $231.3585
Show 2 price lots
- 1,250 shares × $231.37$289K
- 163 shares × $231.27$38K
- Carr PatriciaSVP, Chief Accounting Officer · Nov 4, 2026Option exercise1,250 shares · $175KAvg. price $140.037,925 shares held after
- GALA RENEE DPresident & CEO · Nov 3, 2026Open-market sale1,000 shares · $225KAvg. price $225.37140,394 shares held after
- COZADD BRUCE CDirector · Nov 2, 2026Open-market sale6,000 shares · $1.3MAvg. price $215.84339,875 shares held after
- GALA RENEE DPresident & CEO · Oct 6, 2026Open-market sale2,000 shares · $473KAvg. price $236.4141,394 shares held after
- COZADD BRUCE CDirector · Oct 1, 2026Open-market sale6,000 shares · $1.4MAvg. price $230.33345,875 shares held after
- Patil Neena MEVP & Chief Legal Officer · Sep 10, 2026Open-market sale1,200 shares · $289KAvg. price $240.9447,671 shares held after
- GALA RENEE DPresident & CEO · Sep 8, 2026Open-market sale2,000 shares · $486KAvg. price $243.03143,394 shares held after
- GALA RENEE DPresident & CEO · Sep 8, 2026Shares withheld for taxes1,967 shares · $485KAvg. price $246.81145,394 shares held after
- Henderson Mary ElizabethSVP, Technical Operations · Sep 8, 2026Shares withheld for taxes1,427 shares · $347KAvg. price $243.0107
Show 2 price lots
- 1,412 shares × $243.0299$343K
- 15 shares × $241.2$4K
- COZADD BRUCE CDirector · Sep 1, 2026Open-market sale6,000 shares · $1.5MAvg. price $250.13351,875 shares held after
- Henderson Mary ElizabethSVP, Technical Operations · Aug 31, 2026Shares withheld for taxes2,092 shares · $505KAvg. price $241.4149
Show 2 price lots
- 2,076 shares × $241.39$501K
- 16 shares × $244.6444$4K
- Kennedy PatrickDirector · Aug 31, 2026Shares withheld for taxes1,855 shares · $448KAvg. price $241.4116
Show 2 price lots
- 1,840 shares × $241.39$444K
- 15 shares × $244.0647$4K
- McSharry Heather AnnDirector · Aug 31, 2026Shares withheld for taxes1,855 shares · $448KAvg. price $241.4163
Show 2 price lots
- 1,840 shares × $241.39$444K
- 15 shares × $244.6447$4K
- ENRIGHT PATRICK GDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412KAvg. price $241.4167
Show 2 price lots
- 1,692 shares × $241.39$408K
- 14 shares × $244.6443$3K
- Winningham Rick EDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412KAvg. price $241.4167
Show 2 price lots
- 1,692 shares × $241.39$408K
- 14 shares × $244.6443$3K
- Hamill LauraDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412KAvg. price $241.4119
Show 2 price lots
- 1,692 shares × $241.39$408K
- 14 shares × $244.0643$3K
- Cook Jennifer E.Director · Aug 31, 2026Shares withheld for taxes1,706 shares · $412KAvg. price $241.4119
Show 2 price lots
- 1,692 shares × $241.39$408K
- 14 shares × $244.0643$3K
- Smith Mark DouglasDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412KAvg. price $241.4167
Show 2 price lots
- 1,692 shares × $241.39$408K
- 14 shares × $244.6443$3K
- RIEDEL NORBERT GDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412KAvg. price $241.4167
Show 2 price lots
- 1,692 shares × $241.39$408K
- 14 shares × $244.6443$3K
- COZADD BRUCE CDirector · Aug 31, 2026Shares withheld for taxes1,219 shares · $294KAvg. price $241.4118
Show 2 price lots
- 1,209 shares × $241.3899$292K
- 10 shares × $244.064$2K
- LOVE TED WDirector · Aug 31, 2026Shares withheld for taxes737 shares · $178KAvg. price $241.38992,389 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Jazz Pharmaceuticals (JAZZ) stock information
NASDAQ
Jazz Pharmaceuticals (JAZZ) is listed on NASDAQ. Its market capitalization is about $15.4B. On trailing-twelve-month earnings the P/E ratio is 74.38, and the P/B ratio is 3.67. Return on equity is 4.9%. These figures are computed in-house from official filings and are reference information only.
Jazz Pharmaceuticals — frequently asked questions
- What is the P/E ratio of Jazz Pharmaceuticals (JAZZ)?
- On a trailing-twelve-month basis, JAZZ trades at a P/E ratio of 74.38. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Jazz Pharmaceuticals?
- JAZZ has a market capitalization of about $15.4B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.